De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Venus Medtech (Hangzhou) Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Venus Medtech (Hangzhou) is gedaald met een gemiddeld jaarlijks percentage van -42.6%, terwijl de winst van de Medical Equipment -industrie jaarlijks groeide met 14.7%. De inkomsten zijn groeide met een gemiddeld percentage van 16.9% per jaar.

Belangrijke informatie

-42.6%

Groei van de winst

-34.9%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie	13.7%
Inkomstengroei	16.9%
Rendement op eigen vermogen	-37.6%
Nettomarge	-267.2%
Laatste winstupdate	30 Jun 2023

Recente prestatie-updates uit het verleden

Recent updates

Time To Worry? Analysts Are Downgrading Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Outlook

Apr 07

Is Venus Medtech (Hangzhou) (HKG:2500) Weighed On By Its Debt Load?

Oct 12

Need To Know: Analysts Just Made A Substantial Cut To Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Estimates

Sep 04

We're Not Very Worried About Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Rate

Jul 28

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Are In A Position To Invest In Growth

Mar 29

Are Investors Undervaluing Venus Medtech (Hangzhou) Inc. (HKG:2500) By 43%?

Jan 09

Here's Why We're Not At All Concerned With Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Situation

Dec 01

We're Interested To See How Venus Medtech (Hangzhou) (HKG:2500) Uses Its Cash Hoard To Grow

Aug 16

A Look At The Intrinsic Value Of Venus Medtech (Hangzhou) Inc. (HKG:2500)

Jul 12

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Can Afford To Invest In Growth

Apr 26

Analysts Have Just Cut Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Revenue Estimates By 28%

Apr 05

Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Could Be 23% Above Their Intrinsic Value Estimate

Mar 07

What Type Of Shareholders Make Up Venus Medtech (Hangzhou) Inc.'s (HKG:2500) Share Registry?

Feb 14

Venus Medtech (Hangzhou) Inc. (HKG:2500) Is About To Turn The Corner

Jan 19

Have Insiders Been Selling Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares?

Dec 29

Have Insiders Sold Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Recently?

Dec 29

Can You Imagine How Venus Medtech (Hangzhou)'s (HKG:2500) Shareholders Feel About The 78% Share Price Increase?

Dec 08

Opbrengsten en kosten

Hoe Venus Medtech (Hangzhou) geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

SEHK:2500 Opbrengsten, kosten en inkomsten (CNY Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 23	452	-1,208	500	602
31 Mar 23	429	-1,133	468	565
31 Dec 22	406	-1,058	437	527
30 Sep 22	397	-759	411	451
30 Jun 22	387	-461	382	374
31 Mar 22	401	-417	364	316
31 Dec 21	416	-374	345	258
30 Sep 21	415	-313	320	231
30 Jun 21	413	-252	295	204
31 Mar 21	345	-217	267	186
31 Dec 20	276	-182	239	167
30 Sep 20	252	-210	247	165
30 Jun 20	228	-238	256	163
31 Mar 20	231	-310	289	182
31 Dec 19	233	-381	322	201
31 Dec 18	115	-300	291	105
31 Dec 17	18	-157	56	117

Kwaliteitswinsten: 2500 is momenteel verliesgevend.

Groeiende winstmarge: 2500 is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: 2500 is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 42.6% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van 2500 over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: 2500 is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Medical Equipment industrie ( -4.3% ).

Rendement op eigen vermogen

Hoge ROE: 2500 heeft een negatief Return on Equity ( -37.59% ), omdat het momenteel verliesgevend is.

Venus Medtech (Hangzhou) Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Venus Medtech (Hangzhou) Inc. to Report First Half, 2024 Results on Aug 30, 2024

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: CN¥0.80 loss per share (vs CN¥0.46 loss in 1H 2022)

Venus Medtech (Hangzhou) Inc. to Report First Half, 2023 Results on Aug 31, 2023

First half 2022 earnings: EPS and revenues miss analyst expectations

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.26 loss in 1H 2021)

Recent updates

Venus Medtech (Hangzhou) Inc. Appoints Bing Zhu as the Chief Financial Officer

Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study

Venus Medtech (Hangzhou) Inc. Announces Supervisor and Supervisory Committee Changes

Venus Medtech (Hangzhou) Inc. to Report First Half, 2024 Results on Aug 30, 2024

Venus Medtech Venusp-Valve Completes First Implantation in Ide Pivotal Clinical Study in U.S

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Venus Medtech (Hangzhou) Inc. Announces That Wan Yee Joseph Lau, an Independent Non-Executive Director, the Chairman of the Nomination Committee and A Member of Each of the Remuneration and Assessment Committee and the Audit Committee of the Board, Passed Away

Venus Medtech (Hangzhou) Inc. Appoints Fei Wang as the Chief Financial Officer

Venus Medtech (Hangzhou) Inc. Approves Mr. Liqiao Ma as an Executive Director

New minor risk - Share price stability

Venus Medtech (Hangzhou) Inc. Announces Executive Changes

Is Venus Medtech (Hangzhou) (HKG:2500) A Risky Investment?

No longer forecast to breakeven

Venus Medtech (Hangzhou) Inc. Announces Appointment of Mr. Lim Housen (Lin Haosheng) as Joint Chief Executive Officer with Effect from September 22, 2023

Consensus EPS estimates fall by 24%

No longer forecast to breakeven

First half 2023 earnings released: CN¥0.80 loss per share (vs CN¥0.46 loss in 1H 2022)

Venus Medtech (Hangzhou) Inc. to Report First Half, 2023 Results on Aug 31, 2023

New minor risk - Share price stability

Founder recently bought HK$1.9m worth of stock

Venus Medtech (Hangzhou) Inc., Annual General Meeting, Jun 30, 2023

Venus Medtech (Hangzhou) Inc. Announces Resignation of Haiyue Ma as Joint Company Secretary

Is Venus Medtech (Hangzhou) (HKG:2500) Using Debt In A Risky Way?

Forecast to breakeven in 2025

What Venus Medtech (Hangzhou) Inc.'s (HKG:2500) P/S Is Not Telling You

Time To Worry? Analysts Are Downgrading Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Outlook

Consensus revenue estimates fall by 16%

Forecast to breakeven in 2025

Less than half of directors are independent

Venus Medtech (Hangzhou) Inc. Announces Board Changes

Insider recently sold HK$5.7m worth of stock

Venus Medtech (Hangzhou) Inc. Announces Resignation of Lim Hou-Sen as an Executive Director and Nisa Bernice Wing-Yu Leung as Non-Executive Director and Vice Chairwoman

Less than half of directors are independent

Is Venus Medtech (Hangzhou) (HKG:2500) Weighed On By Its Debt Load?

First half 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 20%

Need To Know: Analysts Just Made A Substantial Cut To Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Estimates

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

First half 2022 earnings released: EPS: CN¥0 (vs CN¥0.26 loss in 1H 2021)

Venus Medtech (Hangzhou) Inc. Announces Change of Employee Representative Supervisor and Chairperson of the Supervisory Committee

Venus Medtech (Hangzhou) Inc. to Report First Half, 2022 Results on Aug 31, 2022

We're Not Very Worried About Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Rate

China's National Medical Products Administration Approves Venusp-Valve, Venus Medtech's In-House Developed Innovative Transcatheter Pulmonic Valve Replacement System

Venus Medtech (Hangzhou) Inc. Announces First American Patient Treated with VenusP-Valve Under Compassionate Use

Full year 2021 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Venus Medtech (Hangzhou) Inc. Announces Expandable Bioprosthetic Dry Tissue Valve Venus-Neo Completed First Clinical Application

Consensus revenue estimates fall by 25%

No longer forecast to breakeven

Venus Medtech (Hangzhou) Inc., Annual General Meeting, May 30, 2022

Forecast breakeven date pushed back to 2023

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Are In A Position To Invest In Growth

Venus Medtech (Hangzhou) Inc. to Report Fiscal Year 2021 Results on Mar 31, 2022

Venus Medtech (Hangzhou) Inc. Appoints Amir Gross as Head of Venus Global Heart Valve Innovation Center

Are Investors Undervaluing Venus Medtech (Hangzhou) Inc. (HKG:2500) By 43%?

Venus Medtech (Hangzhou) Inc. Announces Completion of Global First Clinical Application of Venus-Powerx

Venus Medtech (Hangzhou) Inc. Announces Venus Vitae, Balloon-Expandable Dry Tissue Tavr System Successfully Completed the First Two Implantations in the Fim Clinical Trial

Venus Medtech (Hangzhou) Inc. (SEHK:2500) commences an Equity Buyback Plan for 43,170,744 shares, representing 9.79% of its issued share capital, under the authorization approved on May 21, 2021.

Here's Why We're Not At All Concerned With Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Situation

First half 2021 earnings released: CN¥0.26 loss per share (vs CN¥0.11 loss in 1H 2020)

We're Interested To See How Venus Medtech (Hangzhou) (HKG:2500) Uses Its Cash Hoard To Grow

GM & Executive Director recently bought HK$35m worth of stock

A Look At The Intrinsic Value Of Venus Medtech (Hangzhou) Inc. (HKG:2500)

GM & Executive Director recently bought HK$6.0m worth of stock

GM & Executive Director recently bought HK$30m worth of stock

Forecast breakeven pushed back to 2022

Companies Like Venus Medtech (Hangzhou) (HKG:2500) Can Afford To Invest In Growth

Full year 2020 earnings released: CN¥0.45 loss per share (vs CN¥1.22 loss in FY 2019)

Analysts Have Just Cut Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Revenue Estimates By 28%

National Medical Products Administration of China Approves Venus Medtech's VenusA-Plus Transcatheter Prosthetic Aortic Valve Replacement System - Retrievable Delivery System